Sabby Management LLC decreased its holdings in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 47.0% in the fourth quarter, HoldingsChannel reports. The firm owned 49,000 shares of the biotechnology company’s stock after selling 43,500 shares during the period. Sabby Management LLC’s holdings in Eiger Biopharmaceuticals were worth $684,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 8,748 shares in the last quarter. OxFORD Asset Management LLP bought a new stake in shares of Eiger Biopharmaceuticals during the third quarter valued at approximately $147,000. Unterberg Capital LLC bought a new stake in shares of Eiger Biopharmaceuticals during the fourth quarter valued at approximately $698,000. Renaissance Technologies LLC boosted its holdings in Eiger Biopharmaceuticals by 22.8% in the fourth quarter. Renaissance Technologies LLC now owns 97,013 shares of the biotechnology company’s stock worth $1,353,000 after purchasing an additional 18,000 shares during the last quarter. Finally, P.A.W. Capital Corp boosted its holdings in Eiger Biopharmaceuticals by 25.0% in the fourth quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock worth $1,395,000 after purchasing an additional 20,000 shares during the last quarter. 68.96% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) opened at $9.50 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.85 and a current ratio of 5.85. Eiger Biopharmaceuticals Inc has a one year low of $6.10 and a one year high of $16.20. The firm has a market cap of $96.85, a price-to-earnings ratio of -1.95 and a beta of 1.70.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.09). research analysts expect that Eiger Biopharmaceuticals Inc will post -4.48 earnings per share for the current year.

EIGR has been the topic of several research reports. Oppenheimer set a $34.00 target price on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 7th. ValuEngine cut shares of Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 20th. Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $17.00 target price (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. Eiger Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $27.25.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/03/20/sabby-management-llc-has-684000-holdings-in-eiger-biopharmaceuticals-inc-eigr.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR).

Institutional Ownership by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.